Hamburg, October 19th, 2020: Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the appointment of Klaus Martin, Ph.D., as Chief Executive Officer. Effective August 1, 2020, Dr. Martin replaced Timm Jessen, Ph.D., who resigned for personal reasons. Dr. Jessen will remain with Topas in a consulting capacity to ensure a smooth transition.

Turku, Finland, September 16th, 2020: Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced that Dr Cristina Csimma has been appointed as Chair of the Board of Directors. Cristina brings with her deep expertise in the biopharmaceutical, venture capital, and academic sectors.

This transaction would bring together OncoDNA's expertise in oncology precision medicine and IntegraGen's know-how in DNA sequencing services and bioinformatics analyses. The combination of both companies would enable to offer a complete solution that combines oncology laboratory testing and software solutions which will benefit the treatment of patients with advanced cancer.

SWORD Health's digital MSK therapy now available to Concordia Plan Services membersJune 17th, 2020: Concordia Plan Services, a benefits provider for over 6,000 LCMS organizations worldwide, today announced that they will begin to offer their members access to SWORD Health's digital therapy programs for musculoskeletal pain.Concordia Plan Services, a benefits provider for over 6,000 LCMS organizations worldwide, today announced that they […]

SWORD Health announces key leadership appointmentsJune 15th, 2020: SWORD Health, a digital musculoskeletal and pulmonary therapy provider, today announced the appointment of seven accomplished leaders to their executive team:Erica Pham is named General Counsel. Erica is the former VP of Legal and Government Affairs at Clover Health.Thach "Tak" Nguyen is named Chief Talent Officer. Tak formerly held leadership positions at […]

VENICE, California., May 27th, 2020: DEARhealth Inc., a health tech company focused on AI-powered disease management, announced today the global launch of its DEARhealth platform in the Epic App Orchard online marketplace. DEARhealth offers AI-powered care pathways for multiple chronic conditions and integrates with Electronic Medical Records (EMR) systems, giving providers easy access to goal-oriented recommendations. Organizations using Epic, including health systems, hospitals, and clinics, can now access DEARhealth directly through the marketplace instead of traditional external integration, saving significant time, costs, and staff resources.

New York, February 27th, 2020: SWORD Health (SWORD), a tech-enabled provider of musculoskeletal care, today announced the addition of $9 million to their Series A investment, bringing their total Series A investment to $17 million. The addition was led by Khosla Ventures, with participation from Founders Fund, Green Innovations, Lachy Groom, Vesalius Biocapital and Faber Ventures.

Munich, January 20th, 2020 – Prosthetic feet from the 3D printer are no longer an utopia, but reality. The combination of designing a foot in the computer and fast production through 3D printing creates a completely new ability to act, as Mercuris GmbH proves.

Gosselies, Belgium – February 14th, 2020 – OncoDNA ("OncoDNA or "the Company"), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives.

Munich, Germany / February 10th, 2020. – Successful Munich-based medical technology company Mecuris will be led by a new CEO, Peter Fröhlingsdorf (50), a renowned industry expert. Since the beginning of January this year, Fröhlingsdorf has been managing the business of the up-and-coming medtech scale-up. The main goal for this financial year is to lead the company from the start-up into the growth phase. The CEO's expertise and numerous years of industry know-how will be decisive in this process.